Alliance Global Partners dropped coverage of Vivere Medical (NASDAQ:VIVE) after its pivotal PURSUIT trial in stress urinary incontinence (SUI) in women did not meet its primary endpoint nor several secondary endpoints...
Dawson James initiated coverage of Zomedica (NYSEA:ZOM) with a “buy” rating and price target of $6. The stock closed at 20 cents on Jan. 5. Analyst Jason Kolbert writes that Zomedica is positioning itself as a leading...
Stifel upgraded Sight Sciences (NASDAQ:SGHT) to “buy” from “ hold” and raised its price target to $15 from $10 after a survey of 41 minimally invasive glaucoma surgery (MIGS)-trained ophthalmologists “gives us increased...
Cantor Fitzgerald resumed coverage of Nano-X Imaging (NASDAQ:NNOX) with an “overweight” rating and 12-month price target of $21 after attending the company’s ARC Day in Israel. The stock closed at $7.60 on Jan. 4. The...
H.C. Wainwright initiated coverage of Poseida Therapeutics (NASDAQ:PSTX) with a “buy” rating and $15 price target. The stock closed at $5.79 on Jan. 2. Poseida is a clinical-stage biopharmaceutical company focused on...
Raymond James raised its price target for Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) to $14 from $10, and reiterated its “outperform” rating after the company acquired Great Elm Healthcare for about $80-million. The...
BTIG initiated coverage of Sophia Genetics (NASDAQ:SOPH) with a “buy” rating and $6 price target. The stock price closed at $2.06 on Dec. 30. Sophia is a rapidly growing, global healthcare technology company that sells...
Cantor Fitzgerald raised its price target for Ardelyx (NASDAQ:ARDX) to $3 from $1.60 but maintained a “neutral” rating after a label update from the FDA. The stock closed at $2.51 on Dec. 28. Ardelyx announced that the...
Cantor Fitzgerald launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with an “overweight” rating and a 12-month price target of $3. The stock closed at 80 cents on Dec. 22. X4 is a clinical-stage biopharmaceutical...
Maxim Group initiated coverage of MediWound (NASDAQ:MDWD) with a “buy” rating and $25 price target. The stock closed at $11 on Dec. 21. MediWound is a commercial-stage company developing a bromelain-based platform to...